ReviewCancers2021
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 1 synthesis or guideline pooled it, 296 citations in OpenAlex.
- Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2023Pooled it
- RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.Hepatic oncology · 2026Article
- NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models.Molecular biology reports · 2026Article
- Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters.Hepatology international · 2026Article
- Deciphering the Multiscale Morphology of Somatic Oncogenic Alterations in Hepatocellular Carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways.Molecular biology reports · 2026Article
- Cell line-dependent effects of β‑estradiol and testosterone on aurora kinases, GATA3, and associated miRNAs in hepatocellular carcinoma models HepG2 and Huh‑7.Cancer cell international · 2026Article
- Esculentoside A suppresses the malignant progression of hepatocellular carcinoma by promoting RORB.Cell division · 2026Article
- ETV4 as a potential target gene for alleviating proliferation metastasis of HCC.BMC gastroenterology · 2026Article
- Modulation of Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Gastrointestinal Cancers by Phytochemicals.Pharmaceutical research · 2026Review
- TLCD1 correlates with malignant progression of hepatocellular carcinoma and activation of the ERK signaling cascade.Scientific reports · 2026Article
- Reduction in Hepatic Phosphatidylcholine Biosynthesis Promotes MASH Through Copper Deficiency.bioRxiv : the preprint server for biology · 2026Article
- SLC26A2 as a key regulator and therapeutic target in hepatocellular carcinoma: evidence from pan-cancer and mechanistic studies.Human genomics · 2026Article
- Tomatidine modulatesfibrosis-related markers by promoting autophagy in hepatic stellate cells via the ERK/MAPK-mTOR-ULK1 signaling pathway.Scientific reports · 2026Article
- Research Progress of Treatment of Gouty Arthritis with Chinese Medicine Based on Signal Pathways.Chinese journal of integrative medicine · 2026Review
- Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies.MedComm · 2026Review
- The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.Translational lung cancer research · 2026Review
- A naturally synonymous mutation modulates an ERK-centered regulatory network to mediate thermotolerance divergence in Crassostrea oysters.Communications biology · 2026Article
- Elevated TMEM45B expression promotes liver cancer progression and is associated with MET signaling activation.Scientific reports · 2026Article
- ADAM15 promotes the progression and metastasis of hepatocellular carcinoma by activating the JNK/p38 pathway.Scientific reports · 2026Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC, which are major genetic events leading to the activation of the MAPK/ERK signaling pathway in other cancers. This suggests that there is an alternative mechanism behind the activation of the signaling pathway in HCC. Here, we will review recent advances in understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway and discuss potential therapeutic strategies targeting the signaling pathway in the context of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.